Pertuzumab (Perjeta®) accepted for restricted use within NHS Scotland

Pertuzumab intravenous injection is approved for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence in patients with lymph node-positive disease.

Source:

Scottish Medicines Consortium